AbbVie and Genmab seek to expand use of T cell engager Epkinly

Genmab and AbbVie’s cancer drug Epkinly succeeded in a Phase 3 trial for second-line follicular lymphoma patients, meaning the T cell engager could soon be used to treat patients earlier. In a study of 549 ...